Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 12:2022:7873426.
doi: 10.1155/2022/7873426. eCollection 2022.

Efficacy and Safety of Qinpi Tongfeng Formula in the Treatment of Acute Gouty Arthritis: A Double-Blind, Double-Dummy, Multicenter, Randomized Controlled Trial

Yihua Fan  1   2   3 , Wei Liu  1   2 , Hang Lu  1   2 , Jian Liu  4 , Rui Wu  5 , Jun Zhao  5 , Aihua Wang  1   2 , Xianheng Zhang  4
Affiliations

Efficacy and Safety of Qinpi Tongfeng Formula in the Treatment of Acute Gouty Arthritis: A Double-Blind, Double-Dummy, Multicenter, Randomized Controlled Trial

Yihua Fan et al. Evid Based Complement Alternat Med. .

Abstract

Objective: Traditional Chinese medicine (TCM) has certain curative effect against acute gouty arthritis (AGA), but it lacks high-quality evidence-based studies. In this randomized controlled trial, we try to evaluate the clinical efficacy and safety of Qinpi Tongfeng Formula (QPTFF) in the treatment of AGA.

Methods: One hundred and fourteen patients with AGA (damp heat accumulation syndrome) who met the inclusion and exclusion criteria were randomly divided into treatment group and control group in a ratio of 1 : 1. Patients in the treatment group were treated with QPTFF, and patients in the control group were treated with diclofenac sodium sustained-release tablets for 7 days. The primary outcome measure was the change in visual analog scale (VAS) score for pain from the baseline to day 8. The secondary outcome measures were joint symptom score, TCM syndrome score, total effective rate, pain cure rate, complete pain relief time, patient satisfaction score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum uric acid level. The safety outcome measures were routine blood test, urinalysis, liver function including alanine aminotransferase and aspartate aminotransferase, renal function including blood urea nitrogen and serum creatinine, and the rate of treatment-related adverse events (TRAEs).

Results: 105 patients with 53 in the treatment group and 52 in the control group completed the 7-day treatment. There was no significant difference between two groups in demographic characteristics, VAS score for pain, joint symptom score, TCM syndrome score, ESR, CRP, and serum uric acid level before enrollment at baseline (based on both the full analysis set (FAS) and per protocol set (PPS), P > 0.05). The 95% confidence interval of the difference between the eighth and first VAS score for pain of the two groups was (-0.57, 0.42) in FAS and (-0.48, 0.47) in PPS. The lower bound of both FAS and PPS is greater than the bound value of -0.7. On day 8, there was no significant difference between the two groups in joint symptom score, TCM syndrome score, total effective rate, pain cure rate, complete pain relief time, patient satisfaction score, ESR, and CRP (FAS and PPS, P > 0.05). The serum uric acid level and TRAEs in the treatment group were significantly lower than those in the control group (FAS and PPS, P < 0.05).

Conclusions: QPTFF could alleviate the symptoms of patients with AGA, which is not inferior to diclofenac sodium sustained-release tablets in analgesic. Moreover, QPTFF overmatches diclofenac sodium sustained-release tablets in decreasing serum uric acid level and TRAEs. Therefore, the results provide reliable foundation for QPTTF in the treatment of AGA. Trial Registration. This study protocol was registered in Chinese Clinical Trial Registry (registration number: ChiCTR2100050638).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of AGA patients.
Figure 2
Figure 2
Changes in VAS score for pain between the two groups (FAS).
Figure 3
Figure 3
Changes in VAS scores for pain between the two groups (PPS).
Figure 4
Figure 4
Survival curves for complete pain relief time (FAS).
Figure 5
Figure 5
Survival curves for complete pain relief time (PPS).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Johannsdottir G. A., Palsson O., Jonsson H., Gudbjornsson B. Gout—a treatable condition. Laeknabladid . 2008;104(4):177–186. - PubMed
    1. Piani F., Johnson R. J. Does gouty nephropathy exist, and is it more common than we think? Kidney International . 2021;99(1):31–33. doi: 10.1016/j.kint.2020.10.015. - DOI - PubMed
    1. Ejaz A. A., Nakagawa T., Kanbay M., et al. Hyperuricemia in kidney disease: a major risk factor for cardiovascular events, vascular calcification, and renal damage. Seminars in Nephrology . 2020;40(6):574–585. doi: 10.1016/j.semnephrol.2020.12.004. - DOI - PMC - PubMed
    1. Kaly L., Bilder I., Rozenbaum M., et al. Acute gout sacroiliitis. The Israel Medical Association Journal: The Israel Medical Association Journal . 2021;23(3):191–192. - PubMed
    1. Lorenzo J. P. P., Sollano M. H. M. Z., Salido E. O., et al. 2021 Asia‐pacific league of associations for rheumatology clinical practice guideline for treatment of gout. International Journal of Rheumatic Diseases . 2021;25(1):7–20. doi: 10.1111/1756-185x.14266. - DOI - PubMed